Donepezil Effects on Hippocampal and Prefrontal Functional Connectivity in Alzheimer's Disease: Preliminary Report

Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Journal of Alzheimer's disease: JAD (Impact Factor: 4.15). 08/2012; 31:S221-6. DOI: 10.3233/JAD-2012-120709
Source: PubMed


We used functional connectivity magnetic resonance imaging (fcMRI) to investigate changes in interhemispheric brain connectivity in 11 patients with mild Alzheimer's disease (AD) following eight weeks of treatment with the cholinesterase inhibitor donepezil. We examined functional connectivity between four homologous temporal, frontal, and occipital regions. These regions were selected to represent sites of AD neuropathology, sites of donepezil-related brain activation change in prior studies, and sites that are minimally affected by the pathologic changes of AD. Based on previous findings of selective, localized frontal responses to donepezil, we predicted that frontal connectivity would be most strongly impacted by treatment. Of the areas examined, we found that treatment had a significant effect only on functional connectivity between right and left dorsolateral prefrontal cortices. Implications for understanding the impact of donepezil treatment on brain functioning and behavior in patients with AD are discussed. This preliminary report suggests that fcMRI may provide a useful index of treatment outcome in diseases affecting brain connectivity. Future research should investigate these treatment-related changes in larger samples of patients and age-matched controls.

1 Follower
18 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: Introduction: Donepezil is a highly selective acetylcholinesterase inhibitor and one of the only four drugs currently approved for treatment of Alzheimer's dementia. Providing high bioavailability and a very long half-time, donepezil is regarded as effective and well tolerable in Alzheimer's disease patients, even in difficult clinical conditions such as hepatic or renal impairment. It moderately improves cognitive and global functioning scores in patients with mild to moderate Alzheimer's disease over the course of 6 - 12 months, with open-label extension studies suggesting effects of even longer duration. Areas covered: We summarized relevant pharmacokinetic, pharmacodynamic, clinical trial and neuroimaging data of donepezil. A literature search was performed in the PubMed database; articles published until October 2013 have been considered for this review. Moreover, references from original work and reviews have been searched for further relevant literature. Expert opinion: Donepezil is one of the most frequently prescribed anti-dementia drugs. The recent additional approval of the 23 mg formulation will expand its use in patients with moderate to severe Alzheimer's disease. After numerous Phase III study failures of novel disease-modifying drugs for Alzheimer's disease, donepezil is likely going to stay a first-line therapeutic option in Alzheimer's disease in the upcoming years.
    Expert Opinion on Drug Metabolism &amp Toxicology 04/2014; 10(7). DOI:10.1517/17425255.2014.915028 · 2.83 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Alzheimer's disease (AD) induces a widespread pathological extracellular accumulation of beta-amyloid (Aβ) peptides that affects cortical networks underpinning cognitive functions. This is related to abnormal functional and effective brain connectivity as revealed by graph markers of resting-state eyes-closed electroencephalographic (EEG) rhythms. Here we revised EEG studies in mild cognitive impairment and AD subjects showing that these markers are promising network disease endpoints for basic research and AD drug discovery.
    Drug Discovery Today Therapeutic Strategies 07/2014; 10(2). DOI:10.1016/j.ddstr.2014.02.003
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The multidimensional characterization of complex biomedical systems usually demands a large number of cases in order to obtain reliable inferences. Even so, the number of participants in many studies is relatively small as, for example, in typical clinical trials. Here we suggest an approach based on network visualization, combined with resampling, to discern the patterns of relationships among variables. We illustrate how this can be applied to analyze changes in multiple outcomes in people with dementia. The relationships between several dozens of variables were represented by connectivity graphs, drawn by calculating the relative risk of observing a pair of symptoms in an individual to their co-occurrence by chance only. The statistical significance of the relationships was calculated by generating a bootstrap sample. If the null hypothesis (e.g., the relative risks=1 or equivalently, the pointwise mutual information=0) was rejected, the vertices on the graph representing the variables were connected by an edge. The number of edges (the degree of connectivity) reflects the stage of the cognitive impairment, with worse dementia indicated by lower connectivity. Arranging symptoms consistently allows characteristic profiles to be displayed; this in turn can allow patterns of treatment effects to be discerned, with at-a-glance pattern recognition.
    Model Assisted Statistics and Applications 07/2014; 10(4). DOI:10.1016/j.jalz.2014.05.1430
Show more